• Pfizer allegedly paid an effective tax rate of just 5.4% in 2019 and 2020, despite $364 billion in sales over six years.
  • The company reportedly paid no federal income taxes in 2023 and received a refund, despite $27 billion in U.S. sales revenue.
  • Senator Ron Wyden is leading the charge, calling the practices "egregious" and part of a broader pattern in the pharmaceutical industry.

Wyden Ramps Up Pressure on Pfizer

Senator Ron Wyden, Chair of the Senate Finance Committee, has intensified his investigation into Pfizer's tax strategies, alleging the pharmaceutical giant avoided billions in U.S. taxes through offshore profit-shifting. According to Wyden, Pfizer's effective tax rate plummeted to 5.4% in 2019 and 2020—far below the corporate rate—while generating over $364 billion in global sales during a six-year span.

In 2023, the company reportedly paid no federal income taxes and secured a refund, despite booking $27 billion in U.S. revenue. "This isn’t just aggressive accounting—it’s a blatant dodge," Wyden said in a statement, citing internal committee analysis. Pfizer has not yet publicly responded to the allegations, though a spokesperson confirmed the company complies with all tax laws.

Offshore Strategies Under Fire

Pfizer’s tax approach leans heavily on subsidiaries in low-tax jurisdictions like Ireland, Singapore, and Puerto Rico, where it channels profits from high-revenue drugs like Comirnaty and Paxlovid. The 2017 Trump tax law, which lowered the corporate rate but retained loopholes for offshore income, has facilitated these maneuvers. Critics argue the setup deprives public coffers of funds needed for healthcare and infrastructure.

Meanwhile, Pfizer’s financials remain robust: it posted $63.6 billion in 2024 revenue and reaffirmed 2025 guidance of $61–64 billion. The discrepancy between its financial health and tax contributions has fueled bipartisan frustration. "When working families pay higher rates than a Fortune 50 company, the system is broken," Wyden added.

Broader Implications

The probe mirrors Wyden’s earlier investigations into AbbVie, Merck, and Amgen, suggesting a coordinated push to rein in pharmaceutical tax avoidance. It also arrives as Pfizer eyes expansion into obesity drugs and weighs acquisitions. Any regulatory fallout could complicate those plans—or spur industry-wide changes.

Correction: An earlier version misstated Pfizer’s 2023 U.S. revenue. The figure is $27 billion, not $30 billion.